Erste Asset Management’s Corcept Therapeutics CORT Stock Holding History

Erste Asset Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.61M	Hold	18,300	–	–	0.01%	408
2026 Q1	$698K	Hold	18,300	–	–	0.01%	475
2025 Q4	$1.46M	Hold	18,300	–	–	0.01%	388
2025 Q3	$1.54M	Hold	18,300	–	–	0.01%	373
2025 Q2	$1.34M	Hold	18,300	–	–	0.01%	445
2025 Q1	$1,000K	Buy	+18,300	New	+$1.11M	0.01%	376

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Erste Asset Management's CORT Position: Q2 2026 in Review

Erste Asset Management held its Corcept Therapeutics (CORT) position steady in Q2 2026 at 18,300 shares worth $1.61M. The position accounts for 0.01% of the portfolio, ranked #408.

Erste Asset Management first reported a position in CORT in Q1 2025 and has held it in 6 quarters since. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Erste Asset Management held 18,300 shares of Corcept Therapeutics worth $1.61M as of Q2 2026.
Erste Asset Management left its Corcept Therapeutics share count unchanged in Q2 2026.
Corcept Therapeutics made up 0.01% of Erste Asset Management's portfolio in Q2 2026, its #408 holding.
Erste Asset Management first reported a position in Corcept Therapeutics in Q1 2025 and has held it in 6 quarters since.
422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Erste Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.